OSOussama Ssouni

Oussama Ssouni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oussama Ssouni has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chronic Post-Surgical Pain at 3 Months After Breast Cancer Surgery: Incidence, Predictors, and an Internally Validated Risk Model

    by Abdelilah Ghannam, Mohammed Anass Majbar, Youssef Motiaa, Halima Abahssain, Aiman El Fassi, Oussama Ssouni, Yassine El Bouazizi, Zakaria Houssain Belkhadir, Brahim Elahmadi, Amine Souadka

    Background/Objectives: Chronic post-surgical pain (CPSP) affects 25–60% of women after breast cancer surgery. Prospective data from the Middle East and North Africa (MENA) region remain scarce. This study estimated 3-month CPSP incidence in a Moroccan cohort, developed two internally validated prediction models, and quantified the mediated effects of regional anaesthesia and ketamine through prevention of severe acute postoperative pain. Methods: Prospective cohort of 862 women undergoing curative breast cancer surgery (Institut National d’Oncologie, Rabat; NCT04676438). CPSP was defined as a visual analogue scale (VAS) ≥ 3/10 AND Brief Pain Inventory (BPI) interference ≥ 3/10 at three months. Two logistic regression models were developed (Model A: 7 preoperative variables; Model B: 11 perioperative variables) and internally validated by 1000-bootstrap optimism correction. Counterfactual mediation analysis quantified effects mediated through severe acute pain. Results: CPSP incidence was 39.1% (95% confidence interval (CI) 35.9–42.4%), with 22.6% neuropathic-predominant. Model A showed limited discrimination (area under the curve (AUC) 0.58), with pain catastrophising as the dominant predictor. Model B demonstrated superior performance (AUC 0.694; Brier score 0.209) with net clinical benefit across the 15–55% range of clinically plausible decision thresholds. In counterfactual mediation analysis, an estimated 58.2% and 53.7% of the RA and ketamine effects, respectively, were mediated through severe acute pain, under the framework’s no-unmeasured-confounding assumption. Perioperative ketoprofen independently reduced chronification risk (adjusted odds ratio (aOR) 0.66). Conclusions: In this single-centre Moroccan cohort, 39% of women developed CPSP at three months. Two validated models enable risk stratification at distinct clinical decision points. Regional anaesthesia and ketamine were associated with lower CPSP risk, in a pattern consistent with mediation through prevention of severe acute pain under the model’s assumptions; ketoprofen was independently associated with lower chronification risk. These observational findings are hypothesis-generating and require confirmation before informing changes to analgesic protocols.


  • Open Access

    SCODA: A Low-Cost Prehabilitation Strategy to Improve Outcomes After Cytoreductive Surgery in a Low-Resource Setting

    by Amine Souadka, Lina Alami, Zakaria Elmouatassim, Oumayma Lahnaoui, Yassine El Bouazizi, Sabrillah Echiguer, Oussama Ssouni, Ayman El Fassi, Abdelilah Ghannam, Zakaria Houssain Belkhadir, et al.

    Background: Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) remains the standard of care for peritoneal surface malignancies but carries significant postoperative risks. In low- and middle-income countries (LMICs), the challenge is magnified by limited access to high-cost enhanced recovery programs. The SCODA (Surgical Complication Optimization through Diet and Activity) program was developed as a low-cost prehabilitation intervention to improve outcomes in resource-constrained settings. Methods: This retrospective cohort study included 169 patients undergoing CRS ± HIPEC at a single academic center in Morocco between 2015 and 2023. Patients treated before SCODA implementation (pre-SCODA group, n = 83) were compared to those enrolled in the SCODA program (SCODA group, n = 86). SCODA included oral iron supplementation, a protein-rich food-based diet, and progressive walking sessions over 90 days. Perioperative outcomes, including pulmonary complications, major morbidity (Clavien–Dindo ≥ 3b), transfusions, ICU stay >3 days, and 90-day mortality, were analyzed using univariate and multivariate logistic regression models. Results: The SCODA group had significantly fewer pulmonary complications (2% vs. 13%, p = 0.008), reduced major morbidity (9% vs. 21%, p = 0.031), fewer transfusions (8% vs. 20%, p = 0.024), and shorter ICU stays (median 1.5 vs. 5 days, p < 0.001). Ninety-day mortality was also lower in the SCODA group (5.8% vs. 12.4%, p = 0.046). SCODA participation remained an independent protective factor in multivariate analyses for all endpoints except major complications. Conclusions: The SCODA program is a feasible and effective prehabilitation strategy for improving surgical outcomes after CRS/HIPEC in LMICs. Its low-cost, food-based, and activity-centered design may support broader implementation in resource-limited environments and inform future perioperative care policies in oncology.